Retinitis Pigmentosa: Review of Current Treatment
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Wang, Angeline L. MD; Knight, Darren K. MD; Vu, Thanh-thao T. BSc; Mehta, Mitul C. MD, MS Author Information
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Interim results from the international trial of Second Sight's visual prosthesis
Humayun, M. S., Dorn, J. D., da Cruz, L., Dagnelie, G., Sahel, J.-A., Stanga, P. E., Cideciyan, A. V., Duncan, J. L., Eliott, D., Filley, E., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.09.028 · Cited by 700
Subretinal visual implant alpha IMS - clinical trial interim report
Stingl, K., Bartz-Schmidt, K. U., Besch, D., Chee, C. K., Cottriall, C. L., Gekeler, F., Groppe, M., Jackson, T. L., MacLaren, R. E., Koitschev, A., et al. (2015) · Vision Research · doi:10.1016/j.visres.2015.03.001 · Cited by 387
Five-year safety and performance results from the argus II retinal prosthesis system clinical trial.
da Cruz, L., Dorn, J. D., Humayun, M. S., Dagnelie, G., Handa, J., Barale, P.-O., Sahel, J.-A., Stanga, P. E., Hafezi, F., Safran, A. B., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.06.049 · Cited by 359
da Cruz, L., Coley, B. F., Dorn, J., Merlini, F., Filley, E., Christopher, P., Chen, F. K., Wuyyuru, V., Sahel, J., Stanga, P., et al. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2012-301525 · Cited by 359
Yasuda, S., Liang, M.-H., Marinova, Z., Yahyavi, A., & Chuang, D.-M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002099 · Cited by 358
The Argus® II Retinal Prosthesis System
Luo, Y. H.-L., & da Cruz, L. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.09.003 · Cited by 351
Ahuja, A. K., Dorn, J. D., Caspi, A., McMahon, M. J., Dagnelie, G., daCruz, L., Stanga, P., Humayun, M. S., Greenberg, R. J., & Argus II Study Group (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.179622 · Cited by 289
Chen, P. S., Wang, C.-C., Bortner, C. D., Peng, G.-S., Wu, X., Pang, H., Lu, R.-B., Gean, P.-W., Chuang, D.-M., & Hong, J.-S. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.06.053 · Cited by 262
Stingl, K., Schippert, R., Bartz-Schmidt, K. U., Besch, D., Cottriall, C. L., Edwards, T. L., Gekeler, F., Greppmaier, U., Kiel, K., Koitschev, A., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00445 · Cited by 198
Research works printed but not linked: 75
- Daiger, 2007, Perspective on genes and mutations causing retinitis pigmentosa, Arch Ophthalmol, 125, 151, 10.1001/archopht.125.2.151 · DOI · Paper page
- Berson, 1993, A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa, Arch Ophthalmol, 111, 761, 10.1001/archopht.1993.01090060049022 · DOI · Paper page
- Berson, 2004, Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment, Arch Ophthalmol, 122, 1297, 10.1001/archopht.122.9.1297 · DOI · Paper page
- Berson, 2004, Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses, Arch Ophthalmol, 122, 1306, 10.1001/archopht.122.9.1306 · DOI · Paper page
- Hoffman, 2004, A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa, Am J Ophthalmol, 137, 704
- Hoffman, 2015, Docosahexaenoic acid slows visual field progression in x-linked retinitis pigmentosa: ancillary outcomes of the DHAX trial, Invest Ophthalmol Vis Sci, 56, 6646, 10.1167/iovs.15-17786 · DOI · Paper page
- Berson, 2010, Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A, Arch Ophthalmol, 128, 403, 10.1001/archophthalmol.2010.32 · DOI · Paper page
- Massof, 2010, How strong is the evidence that nutritional supplements slow the progression of retinitis pigmentosa?, Arch Ophthalmol, 128, 493, 10.1001/archophthalmol.2010.46 · DOI
- Massof, 1993, Supplemental vitamin A retards loss of ERG amplitude in retinitis pigmentosa, Arch Ophthalmol, 111, 751, 10.1001/archopht.1993.01090060039019 · DOI · Paper page
- Norton, 1993, A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa, Arch Ophthalmol, 111, 1460, 10.1001/archopht.1993.01090110018003 · DOI
- Siegel, 2013, ω-3 intake in patients with retinitis pigmentosa receiving vitamin A, JAMA Ophthalmol, 131, 267, 10.1001/jamaophthalmol.2013.590 · DOI
- Rayapudi, 2013, Vitamin A and fish oils for retinitis pigmentosa, Cochrane Database Syst Rev, 12, CD008428
- Sibulesky, 1999, Safety of <7500 RE (<25000 IU) vitamin A daily in adults with retinitis pigmentosa, Am J Clin Nutr, 69, 656, 10.1093/ajcn/69.4.656 · DOI
- Wheaton, 2003, Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa, Arch Ophthalmol, 121, 1269, 10.1001/archopht.121.9.1269 · DOI · Paper page
- Hajali, 2008, The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography, Br J Ophthalmol, 92, 1065, 10.1136/bjo.2008.138560 · DOI · Paper page
- Ozdemir, 2005, Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa, Acta Ophthalmol Scand, 83, 248, 10.1111/j.1600-0420.2005.00395.x · DOI
- Garcia-Arumi, 2003, Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa, Ophthalmology, 110, 1164, 10.1016/S0161-6420(03)00259-8 · doi:10.1016/s0161-6420(03)00259-8
- Vinores, 1995, Blood-retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization, Histol Histopathol, 10, 913
- Cox, 1988, Treatment of chronic macular edema with acetazolamide, Arch Ophthalmol, 106, 1190, 10.1001/archopht.1988.01060140350030 · DOI · Paper page
- Fishman, 1989, Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa, Arch Ophthalmol, 107, 1445, 10.1001/archopht.1989.01070020519031 · DOI · Paper page
- Moldow, 1998, The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema, Graefes Arch Clin Exp Ophthalmol, 236, 881, 10.1007/s004170050175 · doi:10.1007/s004170050175
- Chung, 2006, Optical coherence tomography in the diagnosis and monitoring of cystoid macular edema in patients with retinitis pigmentosa, Retina, 26, 922, 10.1097/01.iae.0000250008.83779.23 · doi:10.1097/01.iae.0000250008.83779.23
- Genead, 2010, Efficacy for sustained use of topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and Usher syndrome, Arch Ophthalmol, 128, 1146, 10.1001/archophthalmol.2010.172 · DOI
- Ikeda, 2012, The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa, Graefes Arch Clin Exp Ophthalmol, 250, 809, 10.1007/s00417-011-1904-5 · doi:10.1007/s00417-011-1904-5
- Ikeda, 2013, Therapeutic effect of prolonged treatment with topical dorzolamide for cystoid macular oedema in patients with retinitis pigmentosa, Br J Ophthalmol, 97, 1187, 10.1136/bjophthalmol-2012-303005 · DOI
- Fishman, 2007, Continued use of dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa, Br J Ophthalmol, 91, 743, 10.1136/bjo.2006.107466 · DOI
- Grover, 2006, Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa, Am J Ophthalmol, 141, 850, 10.1016/j.ajo.2005.12.030 · DOI · Paper page
- Liew, 2015, Efficacy and prognostic factors of response to carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa, Invest Ophthalmol Vis Sci, 56, 1531, 10.1167/iovs.14-15995 · DOI
- Apushkin, 2007, Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa, Retina, 27, 1112, 10.1097/IAE.0b013e31805f6b79 · doi:10.1097/iae.0b013e31805f6b79
- Wielders, 2015, Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta-analysis, Am J Ophthalmol, 160, 968, 10.1016/j.ajo.2015.07.032 · doi:10.1016/j.ajo.2015.07.032
- Elma, 2010, Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema, Ophthalmology, 117, 1064, 10.1016/j.ophtha.2010.02.031 · DOI · Paper page
- Scorolli, 2007, Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone, Arch Ophthalmol, 125, 759, 10.1001/archopht.125.6.759 · doi:10.1001/archopht.125.6.759
- Saraiva, 2003, Treatment of cystoid macular edema related to retinitis pigmentosa with intravitreal triamcinolone acetonide, Ophthalmic Surg Lasers Imaging, 34, 398, 10.3928/1542-8877-20030901-11 · doi:10.3928/1542-8877-20030901-11
- Barge, 2013, Intravitreal and subtenon depot triamcinolone as treatment for retinitis pigmentosa associated cystoid macular edema, Case Rep Ophthalmol Med, 2013, 591681
- Schaal, 2016, Subtenon triamcinolone for cystoid macular edema due to retinitis pigmentosa unresponsive to oral acetazolamide, Can J Ophthalmol, 51, e113, 10.1016/j.jcjo.2015.12.021 · doi:10.1016/j.jcjo.2015.12.021
- Srour, 2013, Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa, Graefes Arch Clin Exp Ophthalmol, 251, 1501, 10.1007/s00417-012-2249-4 · doi:10.1007/s00417-012-2249-4
- Saatci, 2013, Bilateral intravitreal dexamethasone implant for retinitis pigmentosa-related macular edema, Case Rep Ophthalmol, 4, 53, 10.1159/000350544 · DOI
- Ahn, 2014, The effect of an intravitreal dexamethasone implant for cystoid macular edema in retinitis pigmentosa: a case report and literature review, Ophthalmic Surg Lasers Imaging Retina, 45, 160, 10.3928/23258160-20140131-03 · DOI
- Örnek, 2016, Intravitreal dexamethasone implant (Ozurdex) for refractory macular edema secondary to retinitis pigmentosa, Turkish J Ophthalmol, 46, 179, 10.4274/tjo.60437 · doi:10.4274/tjo.60437
- Sudhalkar, 2017, Intravitreal dexamethasone implant for recalcitrant cystoid macular edema secondary to retinitis pigmentosa: a pilot study, Graefes Arch Clin Exp Ophthalmol, 255, 1369, 10.1007/s00417-017-3660-7 · DOI
- Mansour, 2018, Intravitreal dexamethasone implant in retinitis pigmentosa-related cystoid macular edema, Retina, 38, 416, 10.1097/IAE.0000000000001542 · DOI
- Querques, 2009, Intravitreal pegaptanib sodium (Macugen) for refractory cystoid macular edema in pericentral retinitis pigmentosa, Int Ophthalmol, 29, 103, 10.1007/s10792-007-9175-1 · doi:10.1007/s10792-007-9175-1
- Melo, 2007, Intravitreal injection of bevacizumab for cystoid macular edema in retinitis pigmentosa, Acta Ophthalmol Scand, 85, 461, 10.1111/j.1600-0420.2006.00872.x · doi:10.1111/j.1600-0420.2006.00872.x
- Yuzbasioglu, 2009, Intravitreal bevacizumab (Avastin) injection in retinitis pigmentosa, Curr Eye Res, 34, 231, 10.1080/02713680802710692 · DOI
- Artunay, 2009, Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa, J Ocul Pharmacol Ther, 25, 545, 10.1089/jop.2009.0089 · DOI
- Moustafa, 2015, Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa—a first case report and short review of the literature, BMC Ophthalmol, 15, 44, 10.1186/s12886-015-0033-z · DOI
- Strong, 2016, Treatment of retinitis pigmentosa-associated cystoid macular oedema using intravitreal aflibercept (Eylea) despite minimal response to ranibizumab (Lucentis): a case report, Case Rep Ophthalmol, 7, 389, 10.1159/000448427 · doi:10.1159/000448427
- Koitschev, 2015, Extraocular surgical approach for placement of subretinal implants in blind patients: lessons from cochlear-implants, J Ophthalmol, 2015, 842518, 10.1155/2015/842518 · DOI
- Noorwez, 2008, A high-throughput screening method for smallmolecule pharmacologic chaperones of misfolded rhodopsin, Invest Ophthalmol Vis Sci, 49, 3224, 10.1167/iovs.07-1539 · DOI
- Monti, 2009, Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection, Curr Mol Pharmacol, 2, 95, 10.2174/1874467210902010095 · doi:10.2174/1874467210902010095 · Paper page
- Clemson, 2011, Therapeutic potential of valproic acid for retinitis pigmentosa, Br J Ophthalmol, 95, 89, 10.1136/bjo.2009.175356 · DOI
- Sisk, 2012, Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa, Br J Ophthalmol, 96, 1154, 10.1136/bjophthalmol-2012-301950 · DOI
- Todd, 2017, Valproic acid for a treatment of retinitis pigmentosa: reasons for optimism and caution, J Neurosci, 37, 5215, 10.1523/JNEUROSCI.0774-17.2017 · DOI
- Shanmugam, 2012, Effect of short-term oral valproic acid on vision and visual field in retinitis pigmentosa, Ophthalmol Ther, 1, 6, 10.1007/s40123-012-0006-8 · doi:10.1007/s40123-012-0006-8
- Kumar, 2014, Efficacy of oral valproic acid in patients with retinitis pigmentosa, J Ocul Pharmacol Ther, 30, 580, 10.1089/jop.2013.0166 · DOI
- Iraha, 2016, Efficacy of valproic acid for retinitis pigmentosa patients: a pilot study, Clin Ophthalmol, 10, 1375, 10.2147/OPTH.S109995 · DOI
- Bhalla, 2013, Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid, Br J Ophthalmol, 97, 895, 10.1136/bjophthalmol-2013-303084 · DOI
- Totan, 2017, The adverse effects of valproic acid on visual functions in the treatment of retinitis pigmentosa, Indian J Ophthalmol, 65, 984, 10.4103/ijo.IJO_978_16 · DOI
- LaVail, 1998, Protection of mouse photoreceptors by survival factors in retinal degenerations, Invest Ophthalmol Vis Sci, 39, 592
- Cayouette, 1998, Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse, J Neurosci, 18, 9282, 10.1523/JNEUROSCI.18-22-09282.1998 · DOI · Paper page
- Tao, 2002, Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa, Invest Ophthalmol Vis Sci, 43, 3292
- Liang, 2011, AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse, Mol Ther, 3, 241, 10.1006/mthe.2000.0252 · DOI · Paper page
- Sieving, 2006, Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants, Proc Natl Acad Sci USA, 103, 3896, 10.1073/pnas.0600236103 · DOI · Paper page
- Birch, 2013, Ciliary neurotrophic factor retinitis pigmentosa study G. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa, Am J Ophthalmol, 156, 283, 10.1016/j.ajo.2013.03.021 · DOI · Paper page
- Tao, 2016, The transcoreal electrical stimulation as a novel therapeutic strategy against retinal and optic neuropathy: a review of experimental and clinical trials, Int J Ophthalmol, 9, 914
- Schatz, 2011, Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled exploratory study, Invest Ophthalmol Vis Sci, 52, 4485, 10.1167/iovs.10-6932 · DOI · Paper page
- Schatz, 2017, Transcorneal Electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled follow-up study over 1 year, Invest Ophthalmol Vis Sci, 58, 257, 10.1167/iovs.16-19906 · DOI · Paper page
- MacLaren, 2016, Gene therapy and stem cell transplantation in retinal disease: the new frontier, Ophthalmology, 123, 98, 10.1016/j.ophtha.2016.06.041 · DOI · Paper page
- Thompson, 2015, Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the monaciano symposium, Invest Ophthalmol Vis Sci, 56, 918, 10.1167/iovs.14-16049 · DOI · Paper page
- Busskamp, 2012, Optogenetic therapy for retinitis pigmentosa, Gene Ther, 19, 169, 10.1038/gt.2011.155 · DOI · Paper page
- Mead, 2015, Stem cell treatment of degenerative eye disease, Stem Cell Res, 14, 243, 10.1016/j.scr.2015.02.003 · DOI · Paper page
- Kim, 2017, Epiretinal membrane formation after intravitreal autologous stem cell implantation in a retinitis pigmentosa patient, Retin Cases Brief Rep, 11, 227, 10.1097/ICB.0000000000000327 · DOI
- Satarian, 2017, Intravitreal injection of bone marrow mesenchymal stem cells in patients with advanced retinitis pigmentosa; a safety study, J Ophthalmic Vis Res, 12, 58, 10.4103/2008-322X.200164 · DOI
- Park, 2015, Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings, Invest Ophthalmol Vis Sci, 56, 81, 10.1167/iovs.14-15415 · DOI · Paper page
- Siqueria, 2011, Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial, Retina, 31, 1207, 10.1097/IAE.0b013e3181f9c242 · DOI
Cited by
More than meets the eye: The role of microglia in healthy and diseased retina
Murenu, E., Gerhardt, M.-J., Biel, M., & Michalakis, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006897 · Cited by 73
MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges
Moustardas, P., Aberdam, D., & Lagali, N. (2023) · Cells · doi:10.3390/cells12040617 · Cited by 63
“RP is typically caused by mutations in key photoreceptor genes, with over 50 genes known to be affected [85].”
BackgroundKarapanos, L., Abbott, C. J., Ayton, L. N., Kolic, M., McGuinness, M. B., Baglin, E. K., Titchener, S. A., Kvansakul, J., Johnson, D., Kentler, W. G., et al. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.10.7 · Cited by 30
Metadata
- Authors
- Wang, A. L., Knight, D. K., Vu, T.-T. T., & Mehta, M. C.
- Venue
- International Ophthalmology Clinics
- Published
- 2019
- Volume
- 59
- Issue
- 1
- Pages
- 263-280
- ISSN
- 0020-8167 (ISSN-L)
- OpenAlex
- W2905827260
- Cited by
- 73
- References
- 15
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Retinitis Pigmentosa: Review of Current Treatment. https://app.cochat.ai/papers/10.1097/iio.0000000000000256
- The paper
- Wang, A. L., Knight, D. K., Vu, T.-T. T., & Mehta, M. C. (2019). Retinitis Pigmentosa: Review of Current Treatment. International Ophthalmology Clinics. https://doi.org/10.1097/iio.0000000000000256
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.